KOSPIRetail & Consumer004080

Shinhung

₩14,340▼ 0.42%2026-11-18 close
Market Cap
₩131.9B
Turnover
₩28,627,540
Volume
2K
Shares out.
9.2M
PER
17.1×
PBR
1.1×
EPS
₩841
Dividend Yield
2.30%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩330 per share · Prices as of the 2026-11-18 close

01

Report overview

Dental supplies base, quarterly earnings swing widens in 2026

Shinhung's revenue has stayed in the KRW 100 billion range since 2022, while controlling shareholders' net income fell in both 2024 and 2025 and quarterly profit has swung sharply through 2026.

  1. 1

    Revenue declined from KRW 118.2 billion in 2022 to KRW 102.6 billion in 2025, and the 2025 increase was only 0.8%.

  2. 2

    Operating profit peaked at KRW 11.4 billion in 2023, fell to KRW 6.28 billion in 2024, and recovered to KRW 7.09 billion in 2025.

  3. 3

    Net income attributable to controlling shareholders was KRW 2.82 billion in 2025, the smallest of 2022 to 2025, and operating cash flow was KRW 1.93 billion.

  4. 4

    Controlling shareholders' net income reached KRW 3.93 billion in the second quarter of 2026, and operating profit in the third quarter rose 19.2 percent year on year to KRW 1.78 billion.

  5. 5

    The debt ratio rose to 29.0 percent at the end of 2025 from 21.8 percent in 2024, but total equity of KRW 116 billion still far exceeds total liabilities of KRW 33.6 billion.

02

Business structure

Shinhung's business is centered on dental products. According to Alphasquare's company overview, main revenue comes from dental consumables, with dental treatment chairs and dental alloys following.

A breakdown in the same source puts product sales at about 69 percent of the mix, with treatment chairs, dental alloys, alloy primary-tooth crowns and other products each in the 5 to 10 percent range, and a leasing segment at 4.6 percent.

The source does not state its reference date, so the mix is read only as a rough guide to structure. Revenue in 2025 was KRW 102.6 billion, below KRW 118.2 billion in 2022. As of September 2023, standalone exports rose 28 percent while domestic sales fell 7.3 percent, so exports partly offset weaker home demand.

A 2024 results summary presented cost reduction and export expansion as the path to improvement, although consolidated revenue for June 2024 fell 8.9 percent year on year. Customers are likely dental clinics and dental laboratories.

Competition comes from domestic and overseas makers of dental consumables and equipment, contested on price, quality and distribution. Shinhung is classified under distribution and consumer goods, but its earnings structure is closer to a manufacturing-style consumables business.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.1B₩1.5B6.2%
2025Q4₩30.4B₩3.2B10.5%
2026Q1₩25.2B₩800M3.2%
2026Q2₩26.3B₩3.6B13.9%
2026Q3₩25.3B₩1.8B7.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩118.2B₩10.5B₩8.2B8.8%7.7%31.6%
2023₩112.4B₩11.4B₩9.2B10.1%8.1%23.2%
2024₩101.8B₩6.3B₩5.2B6.2%4.5%21.8%
2025₩102.6B₩7.1B₩2.8B6.9%2.4%29.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported basis, revenue fell from KRW 118.2 billion in 2022 to KRW 112.4 billion in 2023 (down 4.9 percent year on year) and to KRW 101.8 billion in 2024 (down 9.5 percent), then edged up to KRW 102.6 billion in 2025 (up 0.8 percent). Among 2022 to 2025, 2022 was the largest year and 2024 the smallest.

Operating profit rose from KRW 10.5 billion in 2022 to KRW 11.4 billion in 2023 (up 8.6 percent), dropped sharply to KRW 6.28 billion in 2024 (down 44.7 percent), and recovered to KRW 7.09 billion in 2025 (up 13.0 percent).

The operating margin was 8.8 percent in 2022, 10.1 percent in 2023, 6.2 percent in 2024 and 6.9 percent in 2025, so it has stayed below the 2023 level since 2024.

Net income attributable to controlling shareholders peaked at KRW 9.23 billion in 2023, fell to KRW 5.23 billion in 2024 (down 43.4 percent) and to KRW 2.82 billion in 2025 (down 46.0 percent), declining in both 2024 and 2025.

The similar drops in operating profit (44.7 percent) and controlling net income (43.4 percent) in 2024 suggest the earnings decline began at the operating level.

Total net income for 2025 was KRW 2.93 billion including non-controlling interests, and it should be read separately from the KRW 2.82 billion attributable to controlling shareholders.

By quarter, revenue peaked at KRW 30.4 billion in the fourth quarter of 2025 (up 25.9 percent from the prior quarter), when controlling shareholders recorded a net loss of KRW 312 million, a swing from profit.

Operating profit then fell to KRW 806 million in the first quarter of 2026 (down 74.6 percent from the prior quarter), jumped to KRW 3.64 billion in the second quarter (up 352.3 percent), and fell again to KRW 1.78 billion in the third quarter (down 51.3 percent).

In the second and third quarters of 2026, controlling net income exceeded operating profit, and the non-operating items behind that gap are detailed in the periodic reports. Controlling net income over the last four quarters totaled KRW 7.63 billion.

05

Industry analysis

Shinhung is classified under distribution and consumer goods, but Alphasquare benchmarks it within the medical equipment and supplies industry of 97 listed companies. In that comparison, Shinhung's annual revenue of KRW 102.6 billion compares with an industry average of KRW 86.3 billion, ranking 31st in the group.

Rankings can shift with the reference date and methodology, so they serve only as a directional guide. Demand for dental consumables tends to track treatment volumes and clinic openings and equipment replacement.

Shinhung's revenue has moved within the KRW 100 billion range since 2022, so stability rather than growth has been the defining feature.

A larger export share exposes results to exchange rates and overseas customer demand, and standalone exports rose 28 percent as of September 2023, while domestic sales fell 7.3 percent over the same period.

Competition among domestic dental consumables makers is widely described as fragmented, and comparisons with specific peers rest on the periodic disclosures. The operating margin fell from 10.1 percent in 2023 to 6.9 percent in 2025, so pricing and cost conditions are central to the sector read. Company-specific product mix and export share are likely to matter more to results than broad industry flows.

06

Outlook

Quarterly revenue in 2026 was KRW 25.2 billion in the first quarter, KRW 26.3 billion in the second and KRW 25.3 billion in the third, moving within a narrow band around KRW 25 billion.

Third-quarter revenue rose 5.0 percent year on year but fell 3.7 percent from the prior quarter, so the top-line recovery has been gradual. Profit has swung widely from quarter to quarter, which makes the direction hard to call.

Operating profit of KRW 3.64 billion in the second quarter was the highest of the three quarters, and whether that level repeats is the key point to watch. The next periodic report is the 2026 annual report, which will contain fourth-quarter and full-year 2026 results.

The first test is how full-year 2026 operating profit compares with the KRW 7.09 billion recorded in 2025, which included a KRW 3.17 billion fourth quarter. Export expansion was presented as a route to improvement in a 2024 results summary, and standalone exports had risen 28 percent as of September 2023.

Whether overseas shipments keep growing at that pace in 2026 is a disclosure question. On the domestic side, domestic sales fell 7.3 percent as of September 2023, so the recovery of local customer purchasing is another point to watch.

Controlling net income of KRW 7.63 billion over the last four quarters shows the cumulative scale after quarterly swings.

07

Valuation

PER
17.1×
PBR
1.1×
ROE
6.5%
EPS
₩841
BPS
₩12,838
Dividend per share
₩330

The price-to-earnings ratio moves sharply with earnings, since trailing controlling net income is only KRW 7.63 billion over the last four quarters and KRW 2.82 billion for full-year 2025.

The company posted a controlling net loss in the fourth quarter of 2025 and returned to profit in the first quarter of 2026, so the multiple is sensitive to profit recovery. The price-to-book ratio sits slightly above 1x, which means the premium over net asset value is modest.

Measured against controlling shareholders' equity of KRW 115.4 billion at the end of 2025, the premium to book value is limited. An industry comparison put the dividend yield below the industry average, although that comparison reflects a particular fiscal-year snapshot and may differ from today's level.

When reading the valuation, the historical PER range should be considered alongside quarterly swings in profit. In a quarterly structure with large gaps between profit levels, a single quarter's multiple is unlikely to represent true earning power.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Year-on-year profit recovery by quarter

Controlling net income reached KRW 3.93 billion in the second quarter of 2026, up 406.9 percent from the prior quarter, and third-quarter operating profit of KRW 1.78 billion rose 19.2 percent year on year. Third-quarter revenue of KRW 25.3 billion also grew 5.0 percent year on year.

Controlling net income over the last four quarters totaled KRW 7.63 billion, above the KRW 2.82 billion recorded for full-year 2025.

Balance sheet with low borrowing reliance

Total liabilities at the end of 2025 were KRW 33.6 billion against total equity of KRW 116 billion, so equity is more than three times liabilities. The debt ratio rose to 29.0 percent in 2025 from 23.2 percent in 2023 and 21.8 percent in 2024, but the absolute level remains modest. Equity attributable to controlling shareholders of KRW 115.4 billion makes up most of total equity.

Exports partly offsetting weaker domestic sales

As of September 2023, standalone exports rose 28 percent while domestic sales fell 7.3 percent. A 2024 results summary presented cost reduction and export expansion as improvement measures. If the export share keeps rising, it could cushion softer domestic demand.

09

Bear factors

Flat revenue and shrinking controlling net income

Revenue fell from KRW 118.2 billion in 2022 to KRW 102.6 billion in 2025, and the 2025 increase was only 0.8 percent. Controlling net income dropped from KRW 9.23 billion in 2023 to KRW 2.82 billion in 2025, declining in both 2024 and 2025. Whether profit improves together with revenue is a question for the next annual results.

Shrinking operating cash flow

Operating cash flow fell from KRW 9.58 billion in 2024 to KRW 1.93 billion in 2025. In 2025, operating cash flow of KRW 1.93 billion was below controlling net income of KRW 2.82 billion. Cash generation weakened relative to earnings, so working capital changes need to be checked.

Large swings in quarterly profit

Operating profit fell to KRW 806 million in the first quarter of 2026, down 74.6 percent from the prior quarter, and the fourth quarter of 2025 swung to a controlling net loss of KRW 312 million.

Against KRW 3.64 billion in operating profit in the second quarter of 2026, the gap is wide enough that a single quarter is hard to read as a trend.

10

Risk factors

Product and customer concentration

A large share of revenue depends on dental consumables, so changes in dental treatment demand and customer purchasing cycles can feed directly into sales. With product sales at about 69 percent of the mix, shifts in product mix could also widen profitability swings.

Currency and export dependence

As the export share grows, exchange rate moves and changes in overseas orders affect revenue and margins. The structure has relied on export growth to offset domestic weakness, so a slowdown in exports could weaken revenue resilience.

Gaps between profit levels

In the second and third quarters of 2026, controlling net income exceeded operating profit. Non-operating items and taxes that separate the profit levels can amplify earnings swings, so the detail needs to be checked in the periodic reports. Whether the gap is one-off or recurring changes how earnings quality should be read.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will disclose fourth-quarter and full-year 2026 results. It is the point to check the scale of profit recovery against the 6.9 percent operating margin and KRW 7.09 billion operating profit of 2025.

  2. Mid-May 2027 (quarterly report filing deadline)

    First-quarter 2027 revenue and operating profit will be disclosed. The comparison base is KRW 806 million operating profit and KRW 775 million controlling net income for the first quarter of 2026, and the check is whether the second-quarter 2026 level holds.

  3. Mid-August 2027 (half-year report filing deadline)

    First-half 2027 results will be disclosed. It is the comparison point for judging whether the KRW 3.64 billion operating profit of the second quarter of 2026 was one-off or recurring.

12

Overall view

Shinhung's revenue has moved within the KRW 100 billion range since 2022 on a dental-consumables base, while earnings fell from the 2023 peak through 2025 before showing signs of recovery in 2026 quarterly results.

Full-year 2025 operating profit of KRW 7.09 billion rose 13.0 percent, yet controlling net income of KRW 2.82 billion was the smallest of 2022 to 2025.

In the second quarter of 2026, operating profit of KRW 3.64 billion and controlling net income of KRW 3.93 billion rose together, but third-quarter operating profit fell to KRW 1.78 billion.

Supporting factors include year-on-year quarterly profit gains, a balance sheet with equity well above liabilities, and the export expansion trend. Against them stand flat revenue, the earnings declines in 2024 and 2025, and shrinking operating cash flow in 2025.

Valuation should be read together with the earnings recovery and the multiple on net asset value. The next checkpoints are the fourth-quarter results and operating margin in the 2026 annual report, and the first-quarter 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. accidentalorder.com
  2. comp.fnguide.com
  3. comp.fnguide.com
  4. investing.com
  5. alphasquare.co.kr
  6. comp.fnguide.com
  7. jobkorea.co.kr
  8. v.daum.net
  9. v.daum.net
  10. news.nate.com
  11. indexbox.io
  12. news.nate.com
  13. sellernow.co.kr
  14. thefairnews.co.kr
  15. marketresearchfuture.com
  16. digitaltoday.co.kr
  17. segye.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis